(Yicai) April 22 -- Israel’s Teva Pharmaceutical Industries has teamed up with NeuroGen Pharma to jointly promote the wide availability of migraine treatment Ajovy in China.

NeuroGen Pharma will acquire the exclusive rights for the commercialization of Ajovy in the Chinese mainland from Teva, as well as the exclusive license for the related patents and trademarks, the pair announced. NeuroGen Pharma will also get the marketing authorization for the product in the region.

Ajovy helps patients manage their migraine symptoms over the long term. It was first approved by the United States Food and Drug Administration for adult use in 2018, and then by the European Medicines Agency the following year.

“We are very pleased to have reached this strategic partnership with Teva,” said Chen Penggen, chief executive officer of NeuroGem Pharma. “We will leverage our local expertise and network to bring AJOVY® closer to clinical practice and patient needs in China, ensuring broader and more sustainable access to this globally innovative treatment.”

“Ajovy shows Teva’s long-term investment and continuous innovation in the field of neurology,” said Huang Diren, general manager of Teva. Ajovy is available in over 45 countries and has become the leading preventive injection treatment option for migraines in many of them, he added.

There are about 185 million people suffering from migraines in China, according to the results of a related study.

Founded in 1901, Teva is accelerating its transformation into a globally leading biopharmaceutical company relying on its world-class business foundation in generic drugs and biosimilar drugs.

NeuroGen Pharma is a biopharmaceutical company specialized in neurological treatment. Jointly set up by Singapore’s CBC Group and the United Arab Emirates’ Mubadala Investment, it acquired five mature brand assets in the fields of neurology and allergies of Union Chimique Belge in China, as well as its production base in China’s Zhuhai, in 2024.

Editor: Futura Costaglione